tiprankstipranks
Immutep Ltd (AU:IMM)
ASX:IMM
Australian Market
Want to see AU:IMM full AI Analyst Report?

Immutep Ltd (IMM) Share Forecast & Price Target

153 Followers
See the Price Targets and Ratings of:

IMM Analyst Ratings

Currently, no data available
Based on NaN analysts giving stock ratings to
Immutep
Ltd
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

IMM Stock 12 Month Forecast

There Are No Analyst Ratings for AU:IMM In The Last 3 Months.
Highest Price TargetAverage Price TargetLowest Price Target
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

IMM Financial Forecast

IMM Earnings Forecast

Next quarter’s earnings estimate for IMM is >-AU$0.01 with a range of -AU$0.01 to AU$0.00. The previous quarter’s EPS was -AU$0.03. IMM beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year IMM has Performed in-line its overall industry.
Next quarter’s earnings estimate for IMM is >-AU$0.01 with a range of -AU$0.01 to AU$0.00. The previous quarter’s EPS was -AU$0.03. IMM beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year IMM has Performed in-line its overall industry.

IMM Sales Forecast

Next quarter’s sales forecast for IMM is AU$20.63M with a range of AU$5.33M to AU$28.40M. The previous quarter’s sales results were AU$4.08M. IMM beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year IMM has Performed in-line its overall industry.
Next quarter’s sales forecast for IMM is AU$20.63M with a range of AU$5.33M to AU$28.40M. The previous quarter’s sales results were AU$4.08M. IMM beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year IMM has Performed in-line its overall industry.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bell Potter Analyst forecast on AU:IMM
Bell Potter
Bell Potter
AU$0.65AU$0.07
Hold
0.00%
Upside
Downgraded
03/16/26
Analysts Offer Insights on Healthcare Companies: Telix Pharmaceuticals (Other OTC: TLPPF) and Immutep Ltd (Other OTC: PRRUF)
Jefferies Analyst forecast on AU:IMM
Jefferies
Jefferies
AU$0.04
Hold
-42.86%
Downside
Downgraded
03/13/26
Analysts Offer Insights on Healthcare Companies: Lineage Therap (NYSE MKT: LCTX) and Immutep Ltd (Other OTC: PRRUF)
Canaccord Genuity Analyst forecast on AU:IMM
Canaccord Genuity
Canaccord Genuity
AU$0.4
Buy
471.43%
Upside
Reiterated
03/13/26
Analysts Offer Insights on Healthcare Companies: Immutep Ltd (Other OTC: PRRUF), Coya Therapeutics, Inc. (NASDAQ: COYA) and Rapport Therapeutics, Inc. (NASDAQ: RAPP)
Ord Minnett Analyst forecast on AU:IMM
Unknown Analyst
Ord Minnett
Not Ranked
Ord Minnett
AU$1.5
Buy
2042.86%
Upside
Reiterated
12/18/25
Ord Minnett Sticks to Its Buy Rating for Immutep Ltd (PRRUF)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bell Potter Analyst forecast on AU:IMM
Bell Potter
Bell Potter
AU$0.65AU$0.07
Hold
0.00%
Upside
Downgraded
03/16/26
Analysts Offer Insights on Healthcare Companies: Telix Pharmaceuticals (Other OTC: TLPPF) and Immutep Ltd (Other OTC: PRRUF)
Jefferies Analyst forecast on AU:IMM
Jefferies
Jefferies
AU$0.04
Hold
-42.86%
Downside
Downgraded
03/13/26
Analysts Offer Insights on Healthcare Companies: Lineage Therap (NYSE MKT: LCTX) and Immutep Ltd (Other OTC: PRRUF)
Canaccord Genuity Analyst forecast on AU:IMM
Canaccord Genuity
Canaccord Genuity
AU$0.4
Buy
471.43%
Upside
Reiterated
03/13/26
Analysts Offer Insights on Healthcare Companies: Immutep Ltd (Other OTC: PRRUF), Coya Therapeutics, Inc. (NASDAQ: COYA) and Rapport Therapeutics, Inc. (NASDAQ: RAPP)
Ord Minnett Analyst forecast on AU:IMM
Unknown Analyst
Ord Minnett
Not Ranked
Ord Minnett
AU$1.5
Buy
2042.86%
Upside
Reiterated
12/18/25
Ord Minnett Sticks to Its Buy Rating for Immutep Ltd (PRRUF)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Immutep Ltd

3 Months
Madeleine WilliamsCanaccord Genuity
Success Rate
2/3 ratings generated profit
67%
Average Return
+15.70%
Copying Madeleine Williams's trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +15.70% per trade.
1 Year
Google BiotechnologyTipRanks - Google
Success Rate
0/2 ratings generated profit
0%
Average Return
-15.00%
Copying Google Biotechnology's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -15.00% per trade.
2 Years
Google BiotechnologyTipRanks - Google
Success Rate
0/2 ratings generated profit
0%
Average Return
-15.00%
Copying Google Biotechnology's trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -15.00% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

IMM Analyst Recommendation Trends

Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
4
2
2
1
0
Buy
0
0
0
0
0
Hold
0
2
2
2
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
4
4
4
3
0
In the current month, IMM has received 0 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. IMM average Analyst price target in the past 3 months is .
Each month's total comprises the sum of three months' worth of ratings.

IMM Stock Forecast FAQ

What is AU:IMM’s average 12-month price target, according to analysts?
Currently, no data Available
What is AU:IMM’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for AU:IMM, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
    How can I follow the stock ratings of top Wall Street analysts?
    Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
      Is Immutep Ltd a Buy, Sell or Hold?
      Currently, no data Available
      What is Immutep Ltd’s share price target?
      Currently, no data Available
      What do analysts say about Immutep Ltd?
      Not enough analysts have published a price target to provide an average price target.
      How can I buy shares of Immutep Ltd?
      To buy shares of AU:IMM, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.